The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway.
about
Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D₃Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking regionThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyRegulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3hKSR-2, a vitamin D-regulated gene, inhibits apoptosis in arabinocytosine-treated HL60 leukemia cellsRaf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK moduleVitamin D and differentiation in cancer.Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling.1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors.Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3.MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.1,25-Dihydroxyvitamin D3 induces monocytic differentiation of human myeloid leukemia cells by regulating C/EBPβ expression through MEF2CERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells.Inhibitors for the Vitamin D Receptor-Coregulator Interaction.Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cells.Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1α,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistanceExpression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D(3) and is required for optimal cell differentiationOncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells.Clinical experience using vitamin d and analogs in the treatment of myelodysplasia and acute myeloid leukemia: a review of the literature.Vitamin D3: a helpful immuno-modulator.Highly pathogenic porcine reproductive and respiratory syndrome virus induces prostaglandin E2 production through cyclooxygenase 1, which is dependent on the ERK1/2-p-C/EBP-β pathway.DNA Repair in Despair-Vitamin D Is Not Fair.Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia.Upregulation of the C/EBP β LAP isoform could be due to decreased TNFAIP3/TNIP1 expression in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets.The requirement for and changing composition of the activating protein-1 transcription factor during differentiation of human leukemia HL60 cells induced by 1,25-dihydroxyvitamin D3.
P2860
Q24569633-C9BFE81A-365A-4E35-98B3-CC9442E2C3C6Q24617282-36119170-4C44-48B4-B478-22B41AEEF602Q26799596-E4CE916F-49CB-4D9F-9571-1ED902540E1DQ33622844-39C76581-68C2-4D4B-8E97-3A0EB0DB84A2Q33622860-2A269F86-2FEA-4F04-AE78-BB949CF37B1FQ33622872-0B595578-0180-41D6-B9BB-D38D414C69BAQ33646179-88DD7ADD-B46F-4E25-81E1-320F1F2C063CQ33746077-385B9DAF-AA61-4C48-85D2-BD4E391859A6Q33843653-FABB0479-C4C8-48C2-BDA1-91427DB130D3Q33927891-F2CE7F3E-821C-44BF-A796-1CC2F9D13DD6Q34031476-ACA28C42-B40E-4FD9-BBD8-12EA5720162DQ34206010-E25E427B-44EE-4B37-8D33-61EFFB67B598Q35181504-8A82B3E9-C34B-4AC6-8102-0261E06E7B3CQ35189239-6BD05A22-6632-451F-A029-C61BF4D5B5FFQ35909214-3F6F0FE4-F681-4D80-A553-64B1B9A79B5AQ35929897-E268CCD7-F28C-4CC2-8062-7EE3713C9F83Q35954885-B23E9F6E-424B-491C-8700-E302F8396A8EQ35958335-E61A4C58-D11C-4FDC-9B16-189ABBE3DCFDQ36229398-E48E7228-3DD2-4B5D-8D54-A94DD97AB495Q36417543-4A2B60A0-A5FE-4670-A404-D9BE0F1E8656Q37927252-0390E90F-2CB7-4118-92EC-D0B6E8D09AEBQ38330284-985D4B38-4D1A-4BA2-9064-505F4CB04685Q38874859-B64554D2-A98C-4149-A55C-4F123EEDBC1EQ39037456-C43467A6-95A0-4A26-A93C-4E8148820B2BQ40530266-1195CAF9-922F-4F68-83EE-BDC1BB19A5E4Q41760459-FABEF340-5C7C-403F-8F7B-1DF21AE3253DQ42021323-05CE6EBE-0CEB-469B-AB2B-8F5DD2F2E0FE
P2860
The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
The rationale for deltanoids i ...... ole of KSR-MAPK-C/EBP pathway.
@ast
The rationale for deltanoids i ...... ole of KSR-MAPK-C/EBP pathway.
@en
type
label
The rationale for deltanoids i ...... ole of KSR-MAPK-C/EBP pathway.
@ast
The rationale for deltanoids i ...... ole of KSR-MAPK-C/EBP pathway.
@en
prefLabel
The rationale for deltanoids i ...... ole of KSR-MAPK-C/EBP pathway.
@ast
The rationale for deltanoids i ...... ole of KSR-MAPK-C/EBP pathway.
@en
P2093
P2860
P1476
The rationale for deltanoids i ...... role of KSR-MAPK-C/EBP pathway
@en
P2093
Andrzej Kutner
George P Studzinski
Xuening Wang
Yingyu Zhang
P2860
P356
10.1016/J.JSBMB.2005.06.010
P577
2005-07-25T00:00:00Z